Shandong Sinobioway Biomedicine Co., Ltd.
002581.SZ · SHZ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.89 | -0.01 | 6.71 | -0.22 |
| FCF Yield | -0.64% | -0.42% | -0.83% | -0.76% |
| EV / EBITDA | -18.55 | -40.58 | -93.76 | -97.48 |
| Quality | ||||
| ROIC | -5.15% | -13.60% | -0.09% | 10.25% |
| Gross Margin | 79.78% | 78.29% | 78.66% | 78.69% |
| Cash Conversion Ratio | 0.05 | 0.11 | 0.69 | -0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.31% | 2.19% | 8.86% | -10.81% |
| Free Cash Flow Growth | 61.88% | 52.50% | 19.57% | -117.26% |
| Safety | ||||
| Net Debt / EBITDA | 4.83 | 0.59 | 0.17 | 0.07 |
| Interest Coverage | -436.05 | -32.41 | 3.26 | 29.38 |
| Efficiency | ||||
| Inventory Turnover | 0.91 | 1.09 | 0.95 | 1.33 |
| Cash Conversion Cycle | 368.26 | 259.26 | 358.08 | 341.80 |